On September 5th, 2024, Katherine Scott and Lana Duan from MORSE Consulting presented “Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies” at the CDA-AMC Symposium. They explored how pre-NOC submissions impact market access timelines, using CDA-validated data and insights from our internal database.Download our presentation to learn more about these findings and strategies for accelerating access to new therapies. Panelists We'd like to thank all…
We’re excited to announce that the 2024 Canadian Reimbursement & Forecasting Timelines (CRaFT) Mid-Year Update is now available! If you’re subscribed, you can now access the latest insights and data to enhance your market access strategies here: MORSE Reports Portal Not a subscriber yet? Don’t miss out—subscribe now to stay informed and take advantage of this valuable resource! MORSE Subscriptions
MORSE's Sang Mi Lee joins a podcast with Exactis Innovation discussing the intricacies of Canada's drug reimbursement system and how it might evolve with the recent creation of the Canadian Drug Agency (CDA). Summary: With national pharmacare closer to reality in Canada, our insightful conversation with market access professionals and seasoned pharmacists, Sang Mi Lee, MBA, BSc Phm, RPh and Brian O’Rourke, sheds light on the intricacies of Canada’s drug reimbursement system…
MORSE Consulting Inc. is pleased to release our pCPA Quarterly Update infographic, which highlights key metrics from Q1 2024 compared to performance over the last year. For a more in-depth look at market access trends and timelines comparing 2023 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. …
At MORSE Consulting, we're delighted to share insights from Sherry O'Quinn's recent participation at the Rare Disease Day 2024 Summit held by the Canadian Organization for Rare Disorders (CORD) in Ottawa. The conference, themed around sustaining the momentum of two decades of impactful work in the rare disease community, was insightful and inspiring. Sherry had the opportunity to present a snapshot on the timelines to access for drugs for…
MORSE Consulting Inc. is pleased to release our pCPA Quarterly Update infographic highlighting key metrics from Q4 2023 compared to performance over the last year. For a more in-depth look at market access trends and timelines comparing 2022 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. Please…
MORSE Consulting Inc. is pleased to release our pCPA Quarterly Update infographic highlighting key metrics from Q3 2023 compared to performance over the last year. For a more in-depth look at market access trends and timelines comparing 2022 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. Please…
For a more in-depth look at market access trends and timelines comparing 2022 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. Please contact info@morseconsulting.ca regarding any questions on this infographic or on the CRaFT report. Embed this infographic (copy and paste code) on your website with attribution: <p><a href="https://morseconsulting.ca/morse-consulting-releases-its-pcpa-quarterly-update-q2-2023"><img…
For a more in-depth look at market access trends and timelines comparing 2021 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size OR download PDF. Please contact info@morseconsulting.ca regarding any questions on this infographic or on the CRaFT report. Embed this infographic (copy and paste code) on your website with attribution: <p><a href="https://morseconsulting.ca/morse-consulting-releases-its-pcpa-quarterly-update-q4-2022"><img…
MORSE has been providing monthly data analytics and expert insights through our pCPA updates since 2017. Starting in 2022, MORSE is now publishing the pCPA updates on a quarterly basis. For a more in-depth look at market access trends and timelines comparing 2021 data to that of the past four years, order MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT) report. Click on graphic to print or see full-size…
Toronto, September 7, 2022 – MORSE Consulting is delighted to announce the addition of 2 new team members, Jaclyn Beca and Sang Mi Lee who will enhance MORSE’s reimbursement expertise into pharmacoeconomics, generation and use of real world evidence (RWE) and development of innovative agreements. We are at an exciting time in drug discovery and research as new technologies, such as cell and gene therapies, offer opportunities to treat and…
MORSE has been providing monthly data analytics and expert insights through our pCPA updates since 2017. Starting in 2022, MORSE is now publishing the pCPA updates on a quarterly basis. Last quarter, Keytruda initiated and completed pCPA negotiations 2022-02-11. This was not captured in our previous update, but has since been accounted for in our dataset and the infographic below. For a more in-depth look at market access trends and…
MORSE has been providing data analytics and expert insights through our pCPA updates on a monthly basis since 2017. Starting in 2022, MORSE will be publishing the pCPA updates quarterly instead of monthly. We extend our gratitude to those who provided feedback in anticipation for the transition to a quarterly update. We are pleased to release our first Quarterly pCPA Update Infographic. This resource is aimed at helping market access…
Recently announced changes to CADTH’s Reimbursement Review submission requirements, effective October 2022 necessitates completion of the Sponsor Summary of Clinical Evidence template. The new clinical evidence template is comprehensive, including but not limited to: background information on the clinical condition, current treatment paradigm, unmet need, and place in therapy methods and findings of a systematic literature search for clinical trials of the drug under review summary of evidence from other…
MORSE Consulting is pleased to release our Fifth Annual pCPA Year in Review Infographic – 2021 Edition. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from 2021. This infographic compares year-over-year metrics including: pCPA activity summary; addresses backlog of files under consideration; average time to complete a negotiation; and files adjudicated by the pCPA by type. MORSE Consulting’s Canadian Reimbursement and Forecasting Timelines (CRaFT)…